Compounds > ab103
Page last updated: 2024-11-13

ab103

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

AB103: CD28 mimetic peptide that reduces mortality in experimental models of polymicrobial and gram-negative bacterial infection and sepsis [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71652162
CHEMBL ID3989950
MeSH IDM000604881

Synonyms (23)

Synonym
reltecimod [usan:inn]
d-alanyl-(t-cell-specific surface glycoprotein cd28-(8-15)- peptide)-d-alanine:d-alanyl-l-seryl-l-prolyl-l-methionyl-l-leucyl-l-valyl-l-alanyl-l-tyrosyl-l-alpha-aspartyl-d-alanine immunomodulator
unii-u00j02uy29
d-alanine, d-alanyl-l-seryl-l-prolyl-l-methionyl-l-leucyl-l-valyl-l-alanyl-l-tyrosyl-l-alpha-aspartyl-
ab103
d-alanine, d-alanyl-l-seryl-l-prolyl-l-methionyl-l-leucyl-l-valyl-l-alanyl-l-tyrosyl-l-.alpha.-aspartyl-
reltecimod [inn]
U00J02UY29 ,
d-alanyl-l-seryl-l-prolyl-l-methionyl-l-leucyl-l-valyl-l-alanyl-l-tyrosyl-l-aspartyl-d-alanine
d-alanyl(human t-cell-specific surface glycoprotein cd28-(8-15)-peptidyl)-d-alanine
reltecimod [who-dd]
1447799-33-8
d-alanyl-(t-cell-specific surface glycoprotein cd28-(8-15)- peptide)-d-alanine:d-alanyl-l-seryl-l-prolyl-l-methionyl-l-leucyl-l-valyl-l-alanyl-l-tyrosyl-l-.alpha.-aspartyl-d-alanine immunomodulator
reltecimod
reltecimod [usan]
(5s,8s,11s,14s,17s,20s,23r)-5-((s)-1-((s)-2-((r)-2-aminopropanamido)-3-hydroxypropanoyl)pyrrolidine-2-carboxamido)-20-(carboxymethyl)-17-(4-hydroxybenzyl)-8-isobutyl-11-isopropyl-14,23-dimethyl-6,9,12,15,18,21-hexaoxo-2-thia-7,10,13,16,19,22-hexaazatetrac
CHEMBL3989950
reltecimod (usan/inn)
D11281
Q27290502
CS-0090321
HY-P1698
AKOS040747616

Research Excerpts

Overview

AB103 is a peptide mimetic of the T-lymphocyte receptor, CD28. It is a safe, promising new agent for modulation of inflammation after NSTI.

ExcerptReferenceRelevance
"AB103 is a peptide mimetic of the T-lymphocyte receptor, CD28."( A Novel Drug for Treatment of Necrotizing Soft-Tissue Infections: A Randomized Clinical Trial.
Bulger, EM; Cohen, M; Demetriades, D; Ham, B; Henry, S; Joshi, M; Kaempfer, R; Maier, RV; Maislin, G; Moldawer, LL; Moore, FA; Opal, S; Schreiber, M; Segalovich, I; Shirvan, A; Sperry, J; Talving, P, 2014)		1.12
"AB103 is a safe, promising new agent for modulation of inflammation after NSTI. "( A Novel Drug for Treatment of Necrotizing Soft-Tissue Infections: A Randomized Clinical Trial.
Bulger, EM; Cohen, M; Demetriades, D; Ham, B; Henry, S; Joshi, M; Kaempfer, R; Maier, RV; Maislin, G; Moldawer, LL; Moore, FA; Opal, S; Schreiber, M; Segalovich, I; Shirvan, A; Sperry, J; Talving, P, 2014)		1.85

Treatment

ExcerptReferenceRelevance
"AB103-treated patients had a similar number of debridements (mean [SD], 2.2 [1.1] for the high-dose, 2.3 [1.2] for the low-dose, and 2.8 [2.1] for the placebo groups; P = .56)."( A Novel Drug for Treatment of Necrotizing Soft-Tissue Infections: A Randomized Clinical Trial.
Bulger, EM; Cohen, M; Demetriades, D; Ham, B; Henry, S; Joshi, M; Kaempfer, R; Maier, RV; Maislin, G; Moldawer, LL; Moore, FA; Opal, S; Schreiber, M; Segalovich, I; Shirvan, A; Sperry, J; Talving, P, 2014)		1.12
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (66.67)24.3611
2020's2 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.63 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index36.71 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (50.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other2 (33.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
moxifloxacin
Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.		3.2710aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug
amoxicillin-potassium clavulanate combination
Amoxicillin-Potassium Clavulanate Combination: A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate.		3.2710
ConditionIndicatedRelationship StrengthStudiesTrials
Fasciitis, Necrotizing
A fulminating bacterial infection of the deep layers of the skin and FASCIA. It can be caused by many different organisms, with STREPTOCOCCUS PYOGENES being the most common.		05.5522
Infections, Soft Tissue
[description not available]		06.8442
MODS
[description not available]		03.711
Multiple Organ Failure
A progressive condition usually characterized by combined failure of several organs such as the lungs, liver, kidney, along with some clotting mechanisms, usually postinjury or postoperative.		03.711
Soft Tissue Infections
Infections of non-skeletal tissue, i.e., exclusive of bone, ligaments, cartilage, and fibrous tissue. The concept is usually referred to as skin and soft tissue infections and usually subcutaneous and muscle tissue are involved. The predisposing factors in anaerobic infections are trauma, ischemia, and surgery. The organisms often derive from the fecal or oral flora, particularly in wounds associated with intestinal surgery, decubitus ulcer, and human bites. (From Cecil Textbook of Medicine, 19th ed, p1688)		011.8442
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		04.411
Blood Poisoning
[description not available]		02.1110
E coli Infections
[description not available]		02.1110
Primary Peritonitis
[description not available]		02.1110
Escherichia coli Infections
Infections with bacteria of the species ESCHERICHIA COLI.		02.1110
Peritonitis
INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.		02.1110
Sepsis
Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.		02.1110